SPARQL
Downloads
Documentation/Help
Skip Header
Results
Your Query
Add common prefixes
DESCRIBE <http://purl.uniprot.org/SHA-384/62C064797D9195679D7D1BD8E331C533D8AF021967663BF38466DC4E0698DF941C84C2E1DB32BCF43D5B7D5C87A0311C>
Submit Query
Cancel
RDF/XML
NTriples
Turtle
Show query
Share
Subject
Predicate
Object
http://purl.uniprot.org/SHA-384/62C064797D9195679D7D1BD8E331C533D8AF021967663BF38466DC4E0698DF941C84C2E1DB32BCF43D5B7D5C87A0311C
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://purl.uniprot.org/core/Annotation
http://purl.uniprot.org/SHA-384/62C064797D9195679D7D1BD8E331C533D8AF021967663BF38466DC4E0698DF941C84C2E1DB32BCF43D5B7D5C87A0311C
http://www.w3.org/2000/01/rdf-schema#comment
"A functional interplay between TET2 and p53 during anti-cancer therapy establishes the rationale for targeting TET2 to overcome chemotherapy resistance associated with mutant p53 tumors."
xsd:string
http://purl.uniprot.org/uniprot/#_4977F0129272A4A5F76BA550B7C6FBE2A0F5D19C980CD9197EC8EA4E4AE6E405ED6DBD7D6B341071D9A6935B9DE20223
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
http://purl.uniprot.org/SHA-384/62C064797D9195679D7D1BD8E331C533D8AF021967663BF38466DC4E0698DF941C84C2E1DB32BCF43D5B7D5C87A0311C
http://purl.uniprot.org/uniprot/Q6N021
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/62C064797D9195679D7D1BD8E331C533D8AF021967663BF38466DC4E0698DF941C84C2E1DB32BCF43D5B7D5C87A0311C
http://purl.uniprot.org/uniprot/#_Q6N021-mappedCitation-30390073
http://purl.uniprot.org/core/mappedAnnotation
http://purl.uniprot.org/SHA-384/62C064797D9195679D7D1BD8E331C533D8AF021967663BF38466DC4E0698DF941C84C2E1DB32BCF43D5B7D5C87A0311C